Tonix Pharmaceuticals Holding Gestion

Gestion contrôle des critères 3/4

Le PDG Tonix Pharmaceuticals Holding est Seth Lederman, nommé en Oct2011, a un mandat de 13.08 ans. La rémunération annuelle totale est $ 2.05M, composée du salaire de 32.9% et des bonus 67.1%, y compris les actions et options de la société. détient directement 0% des actions de la société, d'une valeur de $ 27.14. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.3 ans et 6.2 ans.

Informations clés

Seth Lederman

Directeur général

US$2.1m

Rémunération totale

Pourcentage du salaire du PDG	32.9%
Durée du mandat du directeur général	13.1yrs
Propriété du PDG	0.00008%
Durée moyenne d'occupation des postes de direction	6.3yrs
Durée moyenne du mandat des membres du conseil d'administration	6.2yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Seth Lederman a-t-elle évolué par rapport aux bénéfices de Tonix Pharmaceuticals Holding?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$135m
Jun 30 2024	n/a	n/a	-US$149m
Mar 31 2024	n/a	n/a	-US$99m
Dec 31 2023	US$2m	US$675k	-US$117m
Sep 30 2023	n/a	n/a	-US$123m
Jun 30 2023	n/a	n/a	-US$124m
Mar 31 2023	n/a	n/a	-US$123m
Dec 31 2022	US$5m	US$675k	-US$117m
Sep 30 2022	n/a	n/a	-US$112m
Jun 30 2022	n/a	n/a	-US$102m
Mar 31 2022	n/a	n/a	-US$98m
Dec 31 2021	US$8m	US$675k	-US$92m
Sep 30 2021	n/a	n/a	-US$80m
Jun 30 2021	n/a	n/a	-US$73m
Mar 31 2021	n/a	n/a	-US$64m
Dec 31 2020	US$4m	US$614k	-US$52m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$42m
Mar 31 2020	n/a	n/a	-US$34m
Dec 31 2019	US$1m	US$585k	-US$31m
Sep 30 2019	n/a	n/a	-US$31m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$29m
Dec 31 2018	US$1m	US$473k	-US$29m
Sep 30 2018	n/a	n/a	-US$24m
Jun 30 2018	n/a	n/a	-US$24m
Mar 31 2018	n/a	n/a	-US$23m
Dec 31 2017	US$576k	US$473k	-US$21m

Rémunération vs marché: La rémunération totale de Seth ($USD 2.05M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 649.07K ).

Rémunération et revenus: La rémunération de Seth a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Seth Lederman (66 yo)

13.1yrs

Titularisation

US$2,050,065

Compensation

Dr. Seth Lederman, M. D., is a Co-Founder of Tonix Pharmaceuticals Holding Corp. (formerly, Krele Pharmaceuticals) and has been its Chairman, Chief Executive Officer, President and Director since October 7...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Seth Lederman	Co-Founder	13.1yrs	US$2.05m	0.000080% $ 27.1
Bradley Saenger	CFO & Treasurer	8.8yrs	US$904.91k	0% $ 0
Jessica Morris	Chief Operating Officer	8.8yrs	US$928.60k	0% $ 0
Gregory Sullivan	Chief Medical Officer & Secretary	7.7yrs	US$952.00k	0.000010% $ 3.4
Siobhan Fogarty	Executive Vice President of Product Development	no data	pas de données	pas de données
Darryl Rideout	Executive Vice President of Experimental Chemistry	4.8yrs	pas de données	pas de données
Sina Bavari	Executive Vice President of Infectious Disease Research & Development	2.3yrs	pas de données	pas de données
Zeil Rosenberg	Executive Vice President of Medical	1.8yrs	pas de données	pas de données
Thomas Englese	Executive Vice President of Commercial Operations	less than a year	pas de données	pas de données

6.3yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de TNXP est chevronnée et expérimentée (6.3 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Seth Lederman	Co-Founder	13.1yrs	US$2.05m	0.000080% $ 27.1
Adeoye Olukotun	Independent Director	6.2yrs	US$82.48k	0% $ 0
R. Stillwell	Independent Director	1.7yrs	US$113.05k	0% $ 0
David Grange	Independent Director	6.8yrs	US$82.48k	0% $ 0
Margaret Bell	Independent Director	7.2yrs	US$82.48k	0% $ 0
Richard Bagger	Independent Director	4.4yrs	US$82.48k	0% $ 0
Iredell Iglehart	Member of Scientific Advisory Board	no data	pas de données	pas de données
James Treco	Independent Lead Director	5.8yrs	US$102.48k	0% $ 0
Harvey Moldofsky	Member of Scientific Advisory Board	13.4yrs	pas de données	pas de données
Carolyn Taylor	Independent Director	3.3yrs	US$82.48k	0% $ 0

6.2yrs

Durée moyenne de l'emploi

66.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de TNXP sont considérés comme expérimentés (ancienneté moyenne 6.2 ans).

Tonix Pharmaceuticals Holding Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Tonix Pharmaceuticals Holding Corp Announces the Appointment of Thomas Englese as Executive Vice President of Commercial Operations

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 02, 2024

Recent updates

Tonix Pharmaceuticals Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

Tonix Pharmaceuticals Holding Corp. Presents Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024

Tonix Pharmaceuticals Holding Corp Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)

Tonix Pharmaceuticals Holding Corp. Announces its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

Tonix Pharmaceuticals Presents Data on the Potential Mpox Vaccine TNX-801 in Using Synthetic Biology to Battle Mpox Vaccine

Tonix Pharmaceuticals Holding Corp Announces the Appointment of Thomas Englese as Executive Vice President of Commercial Operations

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $10 million worth of its shares.

Tonix Pharmaceuticals Holding Corp. Presents Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium

Tonix Pharmaceuticals Holding Corp. Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication

Tonix Pharmaceuticals Holding Corp. Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, Tnx-801, as Who Declares Mpox Outbreak A Global Health Emergency

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain

Tonix Pharmaceuticals Holding Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Tonix Pharmaceuticals Holding Corp. Announces Potential Positive Impact of U.S. National Academies New Definition of Long COVID on Size of Fibromyalgia Market for Tonmya

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $50 million.

Tonix Pharmaceuticals Holding Corp. Grants Fast Track Designation by FDA for Tonmya for Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Set to File an NDA for Tonmya for the Management of Fibromyalgia, Is Planning Expected Launch in 2H 2025

Tonix Pharmaceuticals Holding Corp. announced that it expects to receive $30 million in funding

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Presents Vaccine Platform Data in Keynote Talk At the Vaccine Congress 2024

Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has completed a Follow-on Equity Offering in the amount of $4.009881 million.

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500

ToniTonix Pharmaceuticals Holding Corp. Presents New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 02, 2024

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $4.4 million.

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society (Acs) Spring 2024 Meeting

Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy

Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers

Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December

Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD

Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of Tnx-102 Sl in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity

Tonix Pharmaceuticals Holding Corp. Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder

National Institute of Allergy and Infectious Diseases Selects Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp. Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs

Tonix Pharmaceuticals Holding Corp. Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving Tnx-1500 (Fc-Modified Dimeric Anti-Cd40l Mab) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models

Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder

Tonix Pharmaceuticals Holding Corp. Announces Poster Presentation Showing Research Results for mTNX-1700

Tonix Pharmaceuticals Holding Corp. Announces Commitment to Supply Tosymra®? (Sumatriptan Nasal Spray) 10 Mg for Treatment of Acute Migraine

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Prevail Proof-Of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID

Tonix Pharmaceuticals Holding Corp. Announces Results of Pre-Ind Meeting with FDA for TNX-801 as A Potential Vaccine to Protect Against Mpox and Smallpox

Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-Modified Humanized Anti-Cd40l Mab) in Healthy Volunteers

Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia

Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder

Tonix Pharmaceuticals Holding Corp. Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023

Tonix Pharmaceuticals Holding Corp. Announces Data Supporting Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, But Not (R)-Tianeptine, in Vivo Rat Novel Object Recognition Test

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘Power’ Study of TNX-1900 Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) and Tonix Medicines, Inc. entered into an agreement to acquire Certain Assets of Upsher Smith Laboratories, LLC for $25 million.

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen